PERTH, Australia – Sydney-based Recce Pharmaceuticals Ltd. completed a placement of AU$27.95 million (US$19.69 million) to advance its synthetic anti-infective pipeline to address antibiotic-resistant superbugs and emerging viral pathogens.
Armata Pharmaceuticals Inc.’s recent $15 million award for a three-year program from the U.S. Department of Defense to partially fund a phase Ib/II study added to the already growing resurgence of notice for phage-based therapeutics, with even big pharma starting to take heed.
LONDON – Novo Repair has made new investments of $12 million, bringing the total invested by the specialist anti-infectives venture capital fund since it was set up two years ago to plug the gap in the early stage pipeline to $48 million.
BOGOTA, Colombia – Researchers at the National University of Córdoba, in Córdoba, Argentina, have developed a technique to optimize the biofunctions of surfaces and inhibit microorganisms such as Staphylococcus aureus from adhering to and building colonies on solid substrates’ surfaces.
After its momentum-building end-of-phase II meeting with the FDA, Contrafect Corp. will start a single phase III trial of exebacase to treat Staphylococcus aureus bacteremia before year-end.